hCG: Evidence, Mechanism, Dosing & Legal Status

Human chorionic gonadotropin (hCG) is a placental glycoprotein hormone that acts as a high-affinity luteinizing-hormone (LH) mimetic, binding the shared LH/CG receptor (LHCGR) on ovarian and testicular cells.3 Unlike the many fitness-market peptides whose claims rest on rodent data alone, hCG is an FDA-approved prescription drug with decades of clinical use — and it is also the subject of one of the most aggressively marketed health frauds in U.S. history. This monograph separates the evidenced reproductive uses from the debunked weight-loss myth.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. hCG is a prescription drug; OTC and homeopathic hCG weight-loss products are illegal in the United States. Dosing figures are reported strictly as seen in approved labeling and published literature for completeness — not as recommendations. Consult a licensed clinician before considering any hormonal therapy.

What is hCG and how does it work?

hCG is a heterodimeric glycoprotein of roughly 237 amino acids and about 36.7 kDa, composed of a 92-amino-acid alpha-subunit (identical to the alpha-subunit shared by LH, FSH and TSH) non-covalently bound to a unique 145-amino-acid beta-subunit.3 The beta-subunit carries a 24-residue C-terminal extension absent from LH-beta; its O-linked glycosylation is largely responsible for hCG's substantially longer circulating half-life than pituitary LH.3 Pharmaceutical hCG is either urine-derived (purified from the urine of pregnant women — Pregnyl, Novarel) or recombinant (choriogonadotropin alfa — Ovidrel).12

The mechanism is well-characterized in humans, not just in animals. hCG and LH activate the same receptor (LHCGR), a G-protein-coupled receptor, and hCG binds it with roughly four to five times higher affinity than LH.3 The FDA label states that the action of hCG is virtually identical to that of pituitary LH, with a small degree of FSH-like activity.1 In males, receptor activation stimulates testicular Leydig cells to produce testosterone — including the high intratesticular testosterone needed for spermatogenesis. In females, it acts as an LH surrogate to trigger final oocyte maturation, luteinization and ovulation, and to support the corpus luteum in progesterone production.12 From a functional, root-cause perspective hCG is notable for restoring an upstream signal (LH) rather than replacing the downstream end-organ product — on TRT it keeps the testis online instead of letting exogenous androgen silence the whole axis.7 Its elimination half-life is roughly 24-36 hours, and subcutaneous and intramuscular routes are essentially bioequivalent by AUC.14

What is the evidence by indication?

hCG is unusual among the compounds covered on PeptideVox because its best uses carry genuine human randomized-controlled-trial and Cochrane-level evidence. The table below grades each indication honestly — note the steep drop from the reproductive uses to the disproven weight-loss claim.

Ovulation triggering (Grade A). hCG is the long-standing standard to mimic the endogenous LH surge and trigger ovulation in ART after FSH-based stimulation. In pivotal RCTs, recombinant choriogonadotropin alfa 250 µg SC was clinically and statistically equivalent to urinary hCG 5,000-10,000 IU IM, and a Cochrane systematic review (Youssef et al., 2016) found no meaningful difference in clinical outcomes between recombinant and urinary hCG for final oocyte maturation — readers can review the protocol at the Cochrane Library.210 The trigger-to-retrieval interval is about 36 hours.2

Intratesticular testosterone (Grade A). In a randomized, dose-ranging trial, 29 healthy men given testosterone enanthate 200 mg/week — which suppressed LH/FSH and crashed intratesticular testosterone by 94% — received concurrent hCG at 125, 250 or 500 IU every other day, or placebo, for three weeks. Intratesticular testosterone rose linearly with hCG dose (P<0.001): 25% below baseline at 125 IU, 7% below at 250 IU, and 26% above baseline at 500 IU.5 This is the mechanistic proof that low-dose hCG preserves the intratesticular androgen milieu spermatogenesis depends on, even under full HPT-axis suppression.

Fertility preservation on TRT (Grade B). A retrospective series of 26 hypogonadal men on TRT plus hCG 500 IU IM every other day showed serum testosterone rising from about 207 to about 1,056 ng/dL while semen parameters were preserved; no man became azoospermic and several contributed to pregnancies.6 Reviews consistently report that low-dose hCG preserves spermatogenesis and testicular volume on TRT, and that higher-dose hCG can reverse TRT-induced azoospermia over about four months.79 It is graded B because the fertility endpoint rests on one small randomized signal plus cohorts, though the intratesticular-testosterone mechanism is RCT-proven.

Cryptorchidism (Grade B-C). hCG is FDA-approved for prepubertal cryptorchidism, but a meta-analysis of RCTs found descent in only about 19% of cases (LHRH about 21%) versus about 4-5% with placebo, with re-ascent in up to a quarter.1112 Given low efficacy, surgery (orchiopexy at 6-12 months) is first-line and hormonal therapy is now discouraged by several authorities.13

What doses appear in the literature?

Reported strictly for informational completeness as seen in approved labeling and published trials — not a protocol or recommendation. For the ovulation/ART trigger, the label describes urinary hCG 5,000-10,000 IU IM, or recombinant choriogonadotropin alfa 250 µg SC (RCT-equivalent), given about 36 hours before retrieval.12 For male hypogonadotropic hypogonadism, labeling describes 1,000-2,000 IU IM two to three times weekly, often with FSH/menotropin added to induce spermatogenesis.1 For TRT-adjunct intratesticular-testosterone or fertility preservation, low-dose roughly 250-500 IU SC/IM every other day is reported in the dose-ranging RCT and clinical series (250 IU near-baseline, 500 IU above baseline).56 Reversal of TRT-induced azoospermia has been reported with higher-dose regimens (~3,000 IU EOD, often with adjunct FSH or a SERM) over about four months.7 Urinary products are lyophilized powders reconstituted for IM use; recombinant Ovidrel is a prefilled 250 µg syringe for SC injection.12

How safe is hCG?

Because hCG is an approved drug, its safety profile is well-documented. In women, the most serious risk is ovarian hyperstimulation syndrome (OHSS) — early warning signs include severe pelvic pain, nausea, weight gain and abdominal distension; OHSS occurred in roughly 1.7-3% with the 250 µg recombinant dose, rising near 9% at 500 µg, and multiple-gestation risk is elevated.2 In men and boys, reported effects include gynecomastia, edema, headache, injection-site pain and — in boys treated for cryptorchidism — precocious puberty, which warrants discontinuation.1 Rare anaphylaxis has been reported with urinary-derived product.1 The FDA has received reports of serious adverse events with hCG used for weight loss — including pulmonary embolism, cardiac arrest and death — though these largely reflect the dangers of extreme calorie restriction rather than a unique hCG toxicity.16 hCG is contraindicated in precocious puberty, androgen-dependent neoplasia such as prostate carcinoma, prior hypersensitivity and pregnancy; because LHCGR is expressed on some tumors and hCG is itself a tumor marker, exogenous dosing also confounds those assays.13

What is the FDA and WADA status in 2026?

hCG is an approved prescription drug: urinary Pregnyl and Novarel (IM) and recombinant Ovidrel (SC), approved for the fertility, hypogonadism and cryptorchidism indications above.12 The key consumer-protection fact is the weight-loss prohibition: there is no FDA-approved hCG weight-loss product, and the FDA and FTC have declared OTC and homeopathic hCG drops, sprays and pellets illegal — selling them violates the FD&C Act and FTC Act, and seven joint warning letters were issued in 2011.1517 hCG cannot legally be sold as a homeopathic medicine for any purpose. Compounded hCG access has also tightened: under the FDA interim bulk-substance policy, the agency stopped categorizing newly nominated bulk substances into interim Category 1 effective January 7, 2025, shifting demand toward FDA-approved branded products.1920

For athletes, the rule is unambiguous: hCG (and LH) are prohibited in males at all times under WADA Section S2.2 because they raise endogenous testosterone; they are not prohibited in females. Legitimate male medical use requires a Therapeutic Use Exemption.2122

Bottom line. hCG is a well-characterized, FDA-approved LH-mimetic with real, RCT-backed value in two domains — triggering ovulation in assisted reproduction and sustaining intratesticular testosterone in men with a suppressed axis, the latter underpinning its increasingly mainstream TRT-adjunct role to preserve fertility (Grade B for that outcome). Used within its evidenced indications by a clinician, it is a genuine tool. Used as a weight-loss product or a self-sourced research chemical, it is unproven and legally proscribed. Regulatory and anti-doping facts here are current as of June 2026 and should be re-verified against the live FDA bulk-substances lists and WADA Prohibited List.